Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.
Jiang X, Pissaloux D, De La Fouchardiere C, Desseigne F, Wang Q, Attignon V, Fondrevelle ME, De La Fouchardiere A, Perol M, Cassier P, Seigne C, Perol D, Ray-Coquard I, Meeus P, Fayette J, Flechon A, Le Cesne A, Penel N, Tredan O, Blay JY. Jiang X, et al. Among authors: fayette j. Oncotarget. 2015 Sep 22;6(28):26388-99. doi: 10.18632/oncotarget.4557. Oncotarget. 2015. PMID: 26317543 Free PMC article.
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Psyrri A, Fayette J, Harrington K, Gillison M, Ahn MJ, Takahashi S, Weiss J, Machiels JP, Baxi S, Vasilyev A, Karpenko A, Dvorkin M, Hsieh CY, Thungappa SC, Segura PP, Vynnychenko I, Haddad R, Kasper S, Mauz PS, Baker V, He P, Evans B, Wildsmith S, Olsson RF, Yovine A, Kurland JF, Morsli N, Seiwert TY; KESTREL Investigators. Psyrri A, et al. Among authors: fayette j. Ann Oncol. 2023 Mar;34(3):262-274. doi: 10.1016/j.annonc.2022.12.008. Epub 2022 Dec 16. Ann Oncol. 2023. PMID: 36535565 Free article. Clinical Trial.
ET-743: a novel agent with activity in soft tissue sarcomas.
Fayette J, Coquard IR, Alberti L, Ranchère D, Boyle H, Blay JY. Fayette J, et al. Oncologist. 2005 Nov-Dec;10(10):827-32. doi: 10.1634/theoncologist.10-10-827. Oncologist. 2005. PMID: 16314293 Free article. Review.
[News of the year 2005 in sarcomas].
Fayette J, Méeus P, Sunyach MP, Thiesse P, Ray Coquard I, Blay JY. Fayette J, et al. Bull Cancer. 2006 Jan;93(1):83-9. Bull Cancer. 2006. PMID: 16455510 Free article. Review. French.
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
Bay JO, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno-Neumann S, Chevreau C, Isambert N, Brain E, Emile G, Le Cesne A, Cioffi A, Kwiatkowski F, Coindre JM, Bui NB, Peyrade F, Penel N, Blay JY; Groupe Sarcome Français. Bay JO, et al. Among authors: fayette j. Int J Cancer. 2006 Aug 1;119(3):706-11. doi: 10.1002/ijc.21867. Int J Cancer. 2006. PMID: 16496406 Clinical Trial.
ET-743: a novel agent with activity in soft-tissue sarcomas.
Fayette J, Coquard IR, Alberti L, Boyle H, Méeus P, Decouvelaere AV, Thiesse P, Sunyach MP, Ranchère D, Blay JY. Fayette J, et al. Curr Opin Oncol. 2006 Jul;18(4):347-53. doi: 10.1097/01.cco.0000228740.70379.3f. Curr Opin Oncol. 2006. PMID: 16721129 Review.
162 results